Charles N York II's Net Worth

$6.1 Million

Estimate Recalculated Nov 11, 2024 01:52PM EST

Who is Charles N York II

Charles N York II has an estimated net worth of $6.1 Million. This is based on reported shares across multiple companies, which include Day One Biopharmaceuticals, Inc., and Aeglea BioTherapeutics, Inc..

SEC CIK

Charles N York II's CIK is 0001655962

Past Insider Trading and Trends

2024 was Charles N York II's most active year for acquiring shares with 11 total transactions. Charles N York II's most active month to acquire stocks was the month of January. 2022 was Charles N York II's most active year for disposing of shares, totalling 16 transactions. Charles N York II's most active month to dispose stocks was the month of April. 2017 saw Charles N York II paying a total of $108,248.94 for 172,459 shares, this is the most they've acquired in one year. In 2024 Charles N York II cashed out on 99,185 shares for a total of $1,201,712.11, their largest year based on trade value.

Loading...

Attention insiders:Dive deeper into market movements and stay ahead of the curve with Benzinga Pro! From up-to-the-second news to audio squawks and interactive data tools, it's everything you need to supercharge your trading strategy. Experience the Benzinga Pro advantage today and transform the way you trade with our exclusive free trial!

Day One Biopharmaceuticals, Inc.

COO, CFO AND SECRETARY
Updated Aug 19, 2024
Form 4
-0.76%
-2.63K
$14.00
-$36.86K
Aug 19, 2024
345.74K
Sale
Aug 15 - Aug 16
Form 4
-0.76%
-2.67K
$16.08
-$43.01K
May 17, 2024
348.37K
Sale
May 15 - May 16
Form 4
-21.77%
-60.46K
$17.88
-$1.08M
May 03, 2024
217.29K
Sale
ScheduledMay 01 - May 03
Form 4
-0.64%
-2.67K
$15.25
-$40.65K
Feb 20, 2024
411.50K
Sale
Feb 15 - Feb 16
Form 4
268.00K
Jan 09, 2024
268.00K
Grant
Jan 05
Form 4
-0.31%
-956.00
$11.69
-$11.18K
Nov 17, 2023
308.17K
Sale
Nov 15 - Nov 16
Form 4
-0.30%
-922.00
$13.86
-$12.78K
Aug 17, 2023
309.13K
Sale
Aug 15 - Aug 17
Form 4
-0.31%
-955.00
$13.12
-$12.53K
May 17, 2023
310.05K
Sale
May 15 - May 16
Form 4
-3.45%
-9.38K
$20.03
-$187.79K
Feb 21, 2023
262.13K
Sale
ScheduledFeb 17
Form 4
-0.29%
-930.00
$19.57
-$18.20K
Feb 17, 2023
320.38K
Sale
Feb 15 - Feb 16
Form 4
-3.59%
-10.00K
$22.75
-$227.52K
Jan 23, 2023
268.81K
Sale
ScheduledJan 20
Form 4
152.00K
Jan 19, 2023
152.00K
Grant
Jan 17
Form 4
-3.49%
-10.00K
$20.07
-$200.65K
Dec 22, 2022
276.50K
Sale
ScheduledDec 20
Form 4
-3.37%
-10.00K
$20.76
-$207.57K
Nov 22, 2022
286.50K
Sale
ScheduledNov 21
Form 4
-0.07%
-430.00
$21.46
-$9.23K
Nov 17, 2022
608.77K
Sale
Nov 15 - Nov 16
Form 4
-3.29%
-10.00K
$20.03
-$200.31K
Nov 03, 2022
294.40K
Sale
ScheduledNov 01
Form 4
-3.18%
-10.00K
$20.05
-$200.47K
Oct 05, 2022
304.40K
Sale
ScheduledOct 03
Form 4
-3.08%
-10.00K
$23.25
-$232.48K
Sep 06, 2022
314.40K
Sale
ScheduledSep 01
Form 4
-0.32%
-1.09K
$24.31
-$26.47K
Aug 17, 2022
342.28K
Sale
Aug 15 - Aug 16
Form 4
-3.02%
-10.00K
$20.05
-$200.54K
Aug 05, 2022
321.37K
Sale
ScheduledAug 04
Form 4
-0.75%
-2.50K
$20.00
-$50.00K
Jul 20, 2022
331.37K
Sale
ScheduledJul 18
Form 4
-0.42%
-1.42K
$20.00
-$28.32K
Jul 12, 2022
333.87K
Sale
ScheduledJul 08
Form 4
-0.68%
-2.28K
$20.00
-$45.58K
Jul 06, 2022
335.28K
Sale
ScheduledJul 01 - Jul 05
Form 4
173.00K
Jan 20, 2022
173.00K
Grant
Jan 18
Form 3
May 26, 2021
337.56K
Showing 25 results

Aeglea BioTherapeutics, Inc.

Chief Financial Officer and VP
Updated Feb 19, 2020
Form 4
126.00K
Feb 19, 2020
126.00K
Grant
Feb 14
Form 4
87.60K
Mar 01, 2019
87.60K
Grant
Feb 28
Form 4
92.10K
Feb 22, 2018
92.10K
Grant
Feb 20
Form 4
294.05%
25.96K
$4.48
$116.22K
Dec 05, 2017
34.79K
Purchase
Aug 15 - Dec 05
Form 4
58.50K
Aug 24, 2017
58.50K
Grant
Aug 22
Form 4
90.00K
Mar 22, 2017
90.00K
Grant
Mar 20
Form 4
55.00K
May 19, 2016
55.00K
Grant
May 17
Form 4
Apr 12, 2016
20.39K
Options
Apr 12
Form 3
Apr 06, 2016
7.50K
Showing 9 results